FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499496406> ?p ?o ?g. }

• W2499496406 endingPage "e144" @default.
• W2499496406 startingPage "e143" @default.
• W2499496406 abstract "Objective: Hyperkalemia is a frequent and potentially life-threatening electrolyte disorder, usually complicating chronic kidney disease (CKD). Factors superimposed to reduced renal function, are further elevating the risk for hyperkalemia development, but their contribution is not fully elucidated in relevant literature. This study aimed to compare the prevalence of hyperkalemia in matched diabetic and non-diabetic patients with CKD and to evaluate factors associated with hyperkalemia occurrence. Design and method: This is a nested case-control study from a cohort of patients followed in a Nephrology outpatient clinic. A total of 180 type-2 diabetic and 180 non-diabetic patients with CKD matched for gender, age and eGFR, were included. Patients with type-1 diabetes or end-stage renal disease were excluded. Prevalence of hyperkalemia was defined as serum potassium > 5 mEq/L and/or use of sodium polystyrene sulfonate, and further by serum potassium levels >5 and greater or equal to 5.2 and 5.5 mEq/L. Prevalence was compared between the two study groups in total population and in CKD Stages separately. Univariate and multivariate logistic regression analysis were conducted to identify factors associated with hyperkalemia occurrence. Results: The prevalence of hyperkalemia was higher in diabetic CKD patients (27.2% vs 20%, p = 0.107) and remained around 30% higher with all secondary definitions used, but never reached statistical significance. In Stage 2 no difference was noted (8.7% vs 17.4%, p = 0.665), in Stage 3 prevalence was significantly higher in diabetics (28.6% vs 17.5%, p = 0.036) and in Stage 4 equally high in both groups (35.5% vs 32.3%, p = 0.788). In multivariate analysis, Stage 4 CKD (OR: 4.535, 95% CI: 1.561–13.173), use of angiotensine-converting enzyme inhibitors (OR: 2.228, 95%CI: 1.254–3.958), and smoking (OR: 2.254, 95%CI: 1.218–4.171) were independently associated with hyperkalemia. Conclusions: Diabetes mellitus is elevating the prevalence of hyperkalemia only in CKD Stage 3 patients (moderately impaired renal function) and this difference is attenuating in CKD Stage 4. Advanced CKD at Stage 4 and ACEIs are major determinants of hyperkalemia occurrence. As the vast majority of patients with CKD belong to Stage 3, the presence of diabetes must be appreciated regarding hyperkalemia risk and relevant therapeutic decisions." @default.
• W2499496406 created "2016-08-23" @default.
• W2499496406 creator A5028159985 @default.
• W2499496406 creator A5053783121 @default.
• W2499496406 creator A5061730396 @default.
• W2499496406 creator A5070275826 @default.
• W2499496406 creator A5085787022 @default.
• W2499496406 date "2016-09-01" @default.
• W2499496406 modified "2023-09-26" @default.
• W2499496406 title "[PP.05.14] PREVALENCE OF HYPERKALEMIA IN MATCHED DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE" @default.
• W2499496406 doi "https://doi.org/10.1097/01.hjh.0000491726.61929.af" @default.
• W2499496406 hasPublicationYear "2016" @default.
• W2499496406 type Work @default.
• W2499496406 sameAs 2499496406 @default.
• W2499496406 citedByCount "0" @default.
• W2499496406 crossrefType "journal-article" @default.
• W2499496406 hasAuthorship W2499496406A5028159985 @default.
• W2499496406 hasAuthorship W2499496406A5053783121 @default.
• W2499496406 hasAuthorship W2499496406A5061730396 @default.
• W2499496406 hasAuthorship W2499496406A5070275826 @default.
• W2499496406 hasAuthorship W2499496406A5085787022 @default.
• W2499496406 hasConcept C126322002 @default.
• W2499496406 hasConcept C134018914 @default.
• W2499496406 hasConcept C159641895 @default.
• W2499496406 hasConcept C2778653478 @default.
• W2499496406 hasConcept C2780243291 @default.
• W2499496406 hasConcept C3020110884 @default.
• W2499496406 hasConcept C555293320 @default.
• W2499496406 hasConcept C71924100 @default.
• W2499496406 hasConceptScore W2499496406C126322002 @default.
• W2499496406 hasConceptScore W2499496406C134018914 @default.
• W2499496406 hasConceptScore W2499496406C159641895 @default.
• W2499496406 hasConceptScore W2499496406C2778653478 @default.
• W2499496406 hasConceptScore W2499496406C2780243291 @default.
• W2499496406 hasConceptScore W2499496406C3020110884 @default.
• W2499496406 hasConceptScore W2499496406C555293320 @default.
• W2499496406 hasConceptScore W2499496406C71924100 @default.
• W2499496406 hasIssue "Supplement 2" @default.
• W2499496406 hasLocation W24994964061 @default.
• W2499496406 hasOpenAccess W2499496406 @default.
• W2499496406 hasPrimaryLocation W24994964061 @default.
• W2499496406 hasRelatedWork W1487494130 @default.
• W2499496406 hasRelatedWork W1975155164 @default.
• W2499496406 hasRelatedWork W2021055445 @default.
• W2499496406 hasRelatedWork W2145027707 @default.
• W2499496406 hasRelatedWork W2493395454 @default.
• W2499496406 hasRelatedWork W2601285714 @default.
• W2499496406 hasRelatedWork W2970908922 @default.
• W2499496406 hasRelatedWork W3007456746 @default.
• W2499496406 hasRelatedWork W4315707061 @default.
• W2499496406 hasRelatedWork W4317543119 @default.
• W2499496406 hasVolume "34" @default.
• W2499496406 isParatext "false" @default.
• W2499496406 isRetracted "false" @default.
• W2499496406 magId "2499496406" @default.
• W2499496406 workType "article" @default.